1Gotschlich E C, Goldschneider I, Artenstein M S. Human immunity to the meningococcus IV. lmmtmogenicity of group A and group C meningococcal ploysaccharides [J]. J Exp Med, 1969; 129:1367-1384.
2Kayhty H, Karanko V, Peltola H et al. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children [J] .J Infect Dis, 1980; 142:861-868.
3Lepow M L, Beeler J, Randolph M et al. Reactogenicity and immunogenici- ty of a quadravalent combined meningococcal polysaccharide vaccine in children [J]. J Infect Dis, 1986; 154:1033-1036.
4Weintraub A. Immunology of bacterial polysaccharide antigens[ J]. Carbo- hydr Res, 2003 ; 338 : 2539-2547.
5Swartley J S, Martin A A, Edupuganti S et al. Capsule swiching of Neisse- ria meningitidis[J]. Proc Natl Acad Sci USA, 1997 ;94:271-276.
6Wang Q, Shao Z, Wang X et al. Genetic study of capsular swiching be- tween Neisseria meningitidis sequence type 7 serogroup A and C strains [J] .Infection and Immunity,2010;78:3883-3888.
7Beddek A J, IJ M S, Kroll J Set al. Martin D R. Evidence for capsule switching between carried and disease-causing Neissefia meningitidis strains[ J ]. Infection and Immunity, 2009 ; 77 : 2989-2994.
8Matthias Frosch, Martin C J Maiden. Handbook of Meningococcal Disease [M]. Weinheim, Germany: WILEY-VCH Verlag GmbH & Co. KGaA, 2006: 343-364.
10Paolo Costantino, Francesco Norelli, Francesco NoreUi et al. Size fraction- ation of bacterial capsular polysaccharides for their use in conjugate vac- cines[J]. Vaccine, 1999; 17:1251-1263.
